Estramustine

DB01196

small molecule approved investigational

Deskripsi

A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.

Struktur Molekul 2D

Berat 440.403
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 20 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

The metabolic urinary patterns of the estradiol moiety of estramustine phosphate and estradiol itself are very similar, although the metabolites derived from estramustine phosphate are excreted at a slower rate.

Interaksi Makanan

2 Data
  • 1. Avoid milk and dairy products.
  • 2. Take on an empty stomach.

Interaksi Obat

500 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Estramustine.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Estramustine.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Estramustine.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Estramustine.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Estramustine.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Estramustine.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Estramustine.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Estramustine.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Estramustine.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Estramustine.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Estramustine.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Estramustine.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Estramustine.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Estramustine.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Estramustine.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Estramustine.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Estramustine.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Estramustine.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Estramustine.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Estramustine.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Estramustine.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Estramustine.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Estramustine.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Estramustine.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Estramustine.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Estramustine.
Cladribine Estramustine may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Estramustine.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Estramustine.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Estramustine.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Estramustine.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Estramustine.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Estramustine.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Estramustine.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Estramustine.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Estramustine.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Estramustine.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Estramustine.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Estramustine.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Estramustine.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Estramustine.
Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Estramustine.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Estramustine.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Estramustine.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Estramustine.
Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Estramustine.
Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Estramustine.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Estramustine.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Estramustine.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Estramustine.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Estramustine.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Estramustine.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Estramustine.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Estramustine.
Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Estramustine.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Estramustine.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Estramustine.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Estramustine.
Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Estramustine.
Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Estramustine.
Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Estramustine.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Estramustine.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Estramustine.
Imatinib The risk or severity of adverse effects can be increased when Imatinib is combined with Estramustine.
Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Estramustine.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Estramustine.
Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Estramustine.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Estramustine.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Estramustine.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Estramustine.
Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Estramustine.
Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Estramustine.
Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Estramustine.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Estramustine.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Estramustine.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Estramustine.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Estramustine.
Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Estramustine.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Estramustine.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Estramustine.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Estramustine.
Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Estramustine.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Estramustine.
Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Estramustine.
Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Estramustine.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Estramustine.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Estramustine.
Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Estramustine.
Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Estramustine.
Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Estramustine.
Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Estramustine.
Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Estramustine.
Capecitabine The risk or severity of adverse effects can be increased when Capecitabine is combined with Estramustine.
Trilostane The risk or severity of adverse effects can be increased when Trilostane is combined with Estramustine.
Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Estramustine.
Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Estramustine.
Idarubicin The risk or severity of adverse effects can be increased when Idarubicin is combined with Estramustine.
Ifosfamide The risk or severity of adverse effects can be increased when Ifosfamide is combined with Estramustine.
Mitoxantrone The risk or severity of adverse effects can be increased when Estramustine is combined with Mitoxantrone.
Lomustine The risk or severity of adverse effects can be increased when Estramustine is combined with Lomustine.

Target Protein

Estrogen receptor beta ESR2
Estrogen receptor ESR1
Microtubule-associated protein 2 MAP2
Microtubule-associated protein 1A MAP1A

Referensi & Sumber

Synthesis reference: Fex, H.J., Hogtierg, K.B., Konyves, I. and Kneip, P.H.0.L; U.S. Patent 3,299,104; Jan. 17, 1967; assigned to Leo AB, Sweden.

Contoh Produk & Brand

Produk: 3 • International brands: 2
Produk
  • Emcyt
    Capsule • 140 mg/1 • Oral • US • Approved
  • Emcyt
    Capsule • 140 mg • Oral • Canada • Approved
  • Emcyt Cap 140mg
    Capsule • 140 mg • Oral • Canada • Approved
International Brands
  • Estracit
  • Estracyt — Pfizer

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul